The patient population and results of the 14-3-3 assay*
| Diagnosis | N | Sc-731 | CG31 | γ 14-3-3 | p value | |||
|---|---|---|---|---|---|---|---|---|
| Pos | Neg | Pos | Neg | Pos | Neg | |||
| *We used three different antibodies to analyse 14-3-3: Sc-731 is the standard polyclonal antisera, γ 14-3-3 (γ directed polyclonal antisera) and the CG31 Biocarta monoclonal antibody. Calculation of the sensitivity, specificity, and PPV of 14-3-3 detection with regard to sCJD diagnosis. | ||||||||
| ALS, amyotrophic lateral sclerosis; Neg, negative; Pos, positive band; PPV, positive predictive value. | ||||||||
| sCJD | 52 | 51 | 1 | 50 | 2 | 50 | 2 | |
| Sensitivity (%) | 98 | 96 | 96 | >0.1 | ||||
| Controls | 201 | 30 | 171 | 16 | 185 | 15 | 186 | |
| Specificity (%) | 85 | 92 | 93 | 0.04 | ||||
| PPV (%) | 63 | 76 | 77 | 0.09 | ||||
| OD | 140 | 14 | 126 | 5 | 135 | 5 | 135 | |
| Frontotemporal dementia | 9 | 0 | 9 | 0 | 9 | 0 | 9 | |
| Alzheimer’s disease | 75 | 5 | 69 | 1 | 34 | 1 | 34 | |
| Vascular dementia | 29 | 4 | 25 | 2 | 16 | 2 | 16 | |
| Lewy body dementia | 28 | 5 | 23 | 2 | 15 | 2 | 15 | |
| Specificity (%) | 90 | 96 | 96 | 0.03 | ||||
| PPV (%) | 78 | 91 | 91 | 0.05 | ||||
| OND | 61 | 16 | 45 | 11 | 50 | 10 | 51 | |
| Multiple system atrophy | 5 | 0 | 5 | 0 | 5 | 0 | 5 | |
| Psychiatric disorders | 11 | 1 | 10 | 0 | 11 | 0 | 11 | |
| Hashimoto’s encephalitis | 5 | 1 | 4 | 0 | 5 | 0 | 5 | |
| ALS | 2 | 1 | 1 | 0 | 2 | 0 | 2 | |
| Paraneoplastic syndrome | 12 | 4 | 8 | 3 | 9 | 3 | 9 | |
| Viral encephalopathy | 15 | 5 | 10 | 4 | 11 | 4 | 11 | |
| Metabolic encephalopathy | 11 | 4 | 7 | 4 | 7 | 3 | 8 | |
| Specificity (%) | 74 | 82 | 84 | 0.19 | ||||
| PPV (%) | 76 | 82 | 82 | >0.1 | ||||